Concord Biotech is an Indian biopharma company that develops and manufactures select fermentation-based APIs for immunosuppressants and oncology. It supplies its products to over 200 customers in 70 countries, including regulated markets such as the United States, Europe, and Japan.
As of March 2022, Concord Biotech had six fermentation-based immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus. It had a total annual installed fermentation capacity of 1,250 cubic meters. The company has two DSIR-approved R&D units with 163 members.
Concord Biotech operates three manufacturing facilities in Gujarat, India. These facilities include API manufacturing facilities in Dholka and Limbasi, and a formulation manufacturing facility in Valthera.